R43HG012526
Project Grant
Overview
Grant Description
Microfluidics platform for spatial multi-omics analysis of tissue at single cell resolution - project summary – abstract
AtlasXomics will develop a transformative single-cell resolution multi-omics platform to help researchers and drug developers understand the cell-cell interactions that drive tissue function and disease. With this SBIR application, AtlasXomics will improve upon its existing deterministic barcoding in tissue for spatial omics sequencing (DBIT-Seq) which combines microfluidics and next generation sequencing (NGS) to enable researchers to spatially map the cell tissue architecture across the transcriptome (~20,000 genes), epigenome (genome-wide chromatin accessibility and histone modifications) and proteome (hundreds of proteins simultaneously).
The platform received significant market interest after its recent publication in Cell in 2020 and its feature in Nature's 2020 Methods of the Year. The spatial omics market has seen rapid growth where in 2020 alone, the spatial transcriptomics field has attracted over $100M in venture capital to address a potential market that is estimated to be as large as $10 billion dollars. However, there is still no spatial omics platform that can achieve both single-cell resolution and comprehensive coverage of the multiple omics to truly decipher the cell-to-cell interactions that drive disease.
By providing single-cell, multi-omic spatial data to as many researchers as possible, AtlasXomics can help enable a new era of discovery into tissue function and disease. DBIT-Seq uniquely utilizes microfluidics to annotate target analytes (mRNA, proteins and/or other biomolecules) in situ (in tissue) with DNA barcodes in a grid of rows and columns, similar to a chessboard, that are then quantified through next-generation sequencing (NGS). The key advantage of this method is that reagents are diffused into tissue, disturbing their biology and spatial configuration as little as possible while creating a high-fidelity molecular image.
Our long-term goal is to industrialize this versatile tool from academic proof-of-concept to a robust, affordable, and scalable discovery platform. In Specific Aim 1, we will develop a new prototype device that achieves single cell resolution by refining our existing microfluidic design. In Specific Aim 2, we will use this device to create detailed single cell multi-omics maps (epigenome, transcriptome and proteome) of the mouse embryo. We will then validate our results by comparing them to standard methods, such as single-cell sequencing, immunofluorescence, and single-molecule fluorescence in situ hybridization (SMFISH).
In Phase II, we plan to scale the platform by improving usability through automation, and by improving performance through expanding the applications of the platform.
AtlasXomics will develop a transformative single-cell resolution multi-omics platform to help researchers and drug developers understand the cell-cell interactions that drive tissue function and disease. With this SBIR application, AtlasXomics will improve upon its existing deterministic barcoding in tissue for spatial omics sequencing (DBIT-Seq) which combines microfluidics and next generation sequencing (NGS) to enable researchers to spatially map the cell tissue architecture across the transcriptome (~20,000 genes), epigenome (genome-wide chromatin accessibility and histone modifications) and proteome (hundreds of proteins simultaneously).
The platform received significant market interest after its recent publication in Cell in 2020 and its feature in Nature's 2020 Methods of the Year. The spatial omics market has seen rapid growth where in 2020 alone, the spatial transcriptomics field has attracted over $100M in venture capital to address a potential market that is estimated to be as large as $10 billion dollars. However, there is still no spatial omics platform that can achieve both single-cell resolution and comprehensive coverage of the multiple omics to truly decipher the cell-to-cell interactions that drive disease.
By providing single-cell, multi-omic spatial data to as many researchers as possible, AtlasXomics can help enable a new era of discovery into tissue function and disease. DBIT-Seq uniquely utilizes microfluidics to annotate target analytes (mRNA, proteins and/or other biomolecules) in situ (in tissue) with DNA barcodes in a grid of rows and columns, similar to a chessboard, that are then quantified through next-generation sequencing (NGS). The key advantage of this method is that reagents are diffused into tissue, disturbing their biology and spatial configuration as little as possible while creating a high-fidelity molecular image.
Our long-term goal is to industrialize this versatile tool from academic proof-of-concept to a robust, affordable, and scalable discovery platform. In Specific Aim 1, we will develop a new prototype device that achieves single cell resolution by refining our existing microfluidic design. In Specific Aim 2, we will use this device to create detailed single cell multi-omics maps (epigenome, transcriptome and proteome) of the mouse embryo. We will then validate our results by comparing them to standard methods, such as single-cell sequencing, immunofluorescence, and single-molecule fluorescence in situ hybridization (SMFISH).
In Phase II, we plan to scale the platform by improving usability through automation, and by improving performance through expanding the applications of the platform.
Awardee
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Connecticut
United States
Geographic Scope
State-Wide
Atlasxomics was awarded
Project Grant R43HG012526
worth $221,977
from National Human Genome Research Institute in May 2022 with work to be completed primarily in Connecticut United States.
The grant
has a duration of 5 months and
was awarded through assistance program 93.172 Human Genome Research.
The Project Grant was awarded through grant opportunity Development of Highly Innovative Tools and Technology for Analysis of Single Cells (SBIR) (R43/R44 Clinical Trial Not Allowed).
SBIR Details
Research Type
SBIR Phase I
Title
Microfluidics Platform for Spatial Multi-Omics Analysis of Tissue at Single Cell Resolution
Abstract
Project Summary – Abstract AtlasXomics will develop a transformative single-cell resolution multi-omics platform to help researchers and drug developers understand the cell-cell interactions that drive tissue function and disease. With this SBIR application, AtlasXomics will improve upon its existing Deterministic Barcoding in Tissue for spatial omics sequencing (DBiT-seq) which combines microfluidics and next generation sequencing (NGS) to enable researchers to spatially map the cell tissue architecture across the transcriptome (~20,000 genes), epigenome (genome-wide chromatin accessibility and histone modifications) and proteome (hundreds of proteins simultaneously). The platform received significant market interest after its recent publication in Cell in 2020 and its feature in Nature’s 2020 methods of the year. The spatial omics market has seen rapid growth where in 2020 alone, the spatial transcriptomics field has attracted over $100M in venture capital to address a potential market that is estimated to be as large as $10 billion dollars. However, there is still no spatial omics platform that can achieve both single-cell resolution and comprehensive coverage of the multiple omics to truly decipher the cell-to-cell interactions that drive disease. By providing single-cell, multi-omic spatial data to as many researchers as possible, AtlasXomics can help enable a new era of discovery into tissue function and disease. DBiT-seq uniquely utilizes microfluidics to annotate target analytes (mRNA, proteins and/or other biomolecules) in situ (in tissue) with DNA barcodes in a grid of rows and columns, similar to a chessboard, that are then quantified through Next-Generation Sequencing (NGS). The key advantage of this method is that reagents are diffused into tissue, disturbing their biology and spatial configuration as little as possible while creating a high-fidelity molecular image. Our long- term goal is to industrialize this versatile tool from academic proof-of-concept to a robust, affordable, and scalable discovery platform. In Specific Aim 1, we will develop a new prototype device that achieves single cell resolution by refining our existing microfluidic design. In Specific Aim 2, we will use this device to create detailed single cell multi-omics maps (epigenome, transcriptome and proteome) of the mouse embryo. We will then validate our results by comparing them to standard methods, such as single-cell sequencing, immunofluorescence, and single-molecule fluorescence in situ hybridization (smFISH). In Phase II, we plan to scale the platform by improving useability through automation, and by improving performance through expanding the applications of the platform.
Topic Code
172
Solicitation Number
PA20-047
Status
(Complete)
Last Modified 4/5/23
Period of Performance
5/1/22
Start Date
10/31/22
End Date
Funding Split
$222.0K
Federal Obligation
$0.0
Non-Federal Obligation
$222.0K
Total Obligated
Activity Timeline
Transaction History
Modifications to R43HG012526
Additional Detail
Award ID FAIN
R43HG012526
SAI Number
R43HG012526-2389322758
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Small Business
Awarding Office
75N400 NIH NATIONAL HUMAN GENOME RESEARCH INSTITUTE
Funding Office
75N400 NIH NATIONAL HUMAN GENOME RESEARCH INSTITUTE
Awardee UEI
LVJJTHPGMQJ9
Awardee CAGE
8MSC0
Performance District
03
Senators
Richard Blumenthal
Christopher Murphy
Christopher Murphy
Representative
Rosa DeLauro
Budget Funding
| Federal Account | Budget Subfunction | Object Class | Total | Percentage |
|---|---|---|---|---|
| National Human Genome Research Institute, National Institutes of Health, Health and Human Services (075-0891) | Health research and training | Grants, subsidies, and contributions (41.0) | $221,977 | 100% |
Modified: 4/5/23